HMGB1 activates replication of latent HIV-1 in a monocytic cell-line, but inhibits HIV-1 replication in primary macrophages. 2006

Piotr Nowak, and Babilonia Barqasho, and Carl Johan Treutiger, and Helena Erlandsson Harris, and Kevin J Tracey, and Jan Andersson, and Anders Sönnerborg
Division of Clinical Virology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden. Piotr.Nowak@labmed.ki.se

High mobility group box protein 1 (HMGB1) is an abundant component of mammalian cells that can be released into extracellular milieu actively or by cells that undergo necrosis. Exposure of inflammatory and endothelial cells to HMGB1 leads to the release of cytokines, including TNF-alpha and IL-6. To evaluate the impact of exogenous HMGB1 on viral replication in HIV-1 infected cells, we studied models of latent and acute infection. Extracellular HMGB1 dose dependently increased HIV-1 replication in the monocytic cells, U1, which is an established model for studying latent HIV-1 infection. Dexamethasone, a known inhibitor of NF-kappaB signaling in U1 cells, inhibited HMGB1-induced stimulation of the viral production. Addition of HMGB1 to primary monocytic cells with active HIV-1 infection elicited the opposite effect, due to suppression of the viral replication. The mechanism of this unexpected finding was explained by an HMGB1-mediated increased release of chemokines (RANTES, MIP-1alpha, and MIP-1beta) that are known to inhibit HIV-1 replication. The stimulatory effect of the HMGB1 was not present when latently infected T-cells (ACH-2) were used as target cells. Our data suggest that extracellular HMGB1 has a dichotomic effect on the HIV-1 infection in monocytes but not in lymphocytes. Both activation of latent HIV-1 infection and inhibition of active replication can thus be seen in vitro.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine

Related Publications

Piotr Nowak, and Babilonia Barqasho, and Carl Johan Treutiger, and Helena Erlandsson Harris, and Kevin J Tracey, and Jan Andersson, and Anders Sönnerborg
December 2008, Biological & pharmaceutical bulletin,
Piotr Nowak, and Babilonia Barqasho, and Carl Johan Treutiger, and Helena Erlandsson Harris, and Kevin J Tracey, and Jan Andersson, and Anders Sönnerborg
October 1999, AIDS (London, England),
Piotr Nowak, and Babilonia Barqasho, and Carl Johan Treutiger, and Helena Erlandsson Harris, and Kevin J Tracey, and Jan Andersson, and Anders Sönnerborg
March 2008, Current HIV research,
Piotr Nowak, and Babilonia Barqasho, and Carl Johan Treutiger, and Helena Erlandsson Harris, and Kevin J Tracey, and Jan Andersson, and Anders Sönnerborg
August 2006, Microbes and infection,
Piotr Nowak, and Babilonia Barqasho, and Carl Johan Treutiger, and Helena Erlandsson Harris, and Kevin J Tracey, and Jan Andersson, and Anders Sönnerborg
August 1997, The American journal of physiology,
Piotr Nowak, and Babilonia Barqasho, and Carl Johan Treutiger, and Helena Erlandsson Harris, and Kevin J Tracey, and Jan Andersson, and Anders Sönnerborg
January 1982, Acta cytologica,
Piotr Nowak, and Babilonia Barqasho, and Carl Johan Treutiger, and Helena Erlandsson Harris, and Kevin J Tracey, and Jan Andersson, and Anders Sönnerborg
December 2015, Journal of physiology and biochemistry,
Piotr Nowak, and Babilonia Barqasho, and Carl Johan Treutiger, and Helena Erlandsson Harris, and Kevin J Tracey, and Jan Andersson, and Anders Sönnerborg
August 2013, Journal of leukocyte biology,
Piotr Nowak, and Babilonia Barqasho, and Carl Johan Treutiger, and Helena Erlandsson Harris, and Kevin J Tracey, and Jan Andersson, and Anders Sönnerborg
April 2018, JCI insight,
Piotr Nowak, and Babilonia Barqasho, and Carl Johan Treutiger, and Helena Erlandsson Harris, and Kevin J Tracey, and Jan Andersson, and Anders Sönnerborg
March 2000, European cytokine network,
Copied contents to your clipboard!